艾美捷科技代理Boneslices品牌全系列产品

Boneslices是一家来自丹麦的公司，专注于生产牛皮质骨片。Boneslices公司提供用于200um, 400um厚度破骨细胞骨吸收功能检测Boneslice骨切片，适用于96孔板检测。

▍Boneslices产品介绍

在开始陷窝实验前，需用培养基对骨切片进行复水处理。由外周血单核细胞（PBMC）或共培养体系生成的成熟/未成熟破骨细胞，均可接种于骨切片表面。根据破骨细胞的成熟状态及存在因子的差异，吸收陷窝将在3-14天内形成。通过抗酒石酸酸性磷酸酶（TRAcP）活性检测可观察破骨细胞数量，而甲苯胺蓝染色则可显现吸收陷窝与吸收沟的形成（见图2）。

▍产品参数

产品描述：本品为用于破骨细胞骨吸收实验的皮质骨切片。

规格参数：直径：6mm（适配96孔板）

厚度：0.2mm（最适用免疫荧光、共聚焦显微镜及延时记录）；0.4mm（最适用下游分析）

运输条件：骨切片在室温环境下运输。

用途说明：牛皮质骨切片专为96孔板中的破骨细胞陷窝/骨吸收实验设计。

Lunginnov公司位于法国里尔市，主要产品线包括生命科学试剂和体外诊断医疗器械。Lunginnov公司最大的特色是为研究者提供Endocan和CG-Cleaved Endocan检测产品（包括抗体、ELISA试剂盒、重组蛋白等），这两个分子已经被证明是肺部感染/损伤的标志分子。

Lunginnov develops innovative solutions for respiratory diseases that enable earlier therapeutic decision to be helpful for patients. Lunginnov markets 2 product lines:

A range of unique reagents for research in Life Sciences

A range of original medical devices for In Vitro Diagnostic

Lunginnov is declared manufacturer to the french regulatory agency ANSM. The company devotes a significant part of its budget to its internal R&D and to set up collaborative projects with Research Centers in France and abroad. Lunginnov is specialized on endocan and CG-cleaved endocan as markers of lung infection/injury, by proposing specific tools of high quality researchers and clinicians.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Allele Biotechnology位于美国圣地亚哥市，主要专注于对生物过程的机制进行探索，以开发生物医学及治疗相关的技术和产品。以各个物种的iPS细胞、人类cGMP iPS细胞及衍生的细胞为材料，Allele Biotechnology利用专利性的非整合细胞编辑方法，开发了出了细胞治疗和药物筛选的技术。Allele Biotechnology具有深厚的基因组修饰和细胞荧光报告因子的经验，为客户提供优异的细胞检测解决方案。Allele Biotechnology还提供荧光蛋白、高效荧光素酶底物、基因分型试剂盒、骆驼抗体等产品；此外还在RNA干扰领域尤其独特的专利。

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to develop cell therapy and enable drug discovery through the use of human and non-human primate iPS cells, cGMP-grade human iPS cells and their derivatives. With additional expertise in genome modification and unique cell-based fluorescence sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of advanced research tools including superior fluorescent proteins, highly efficient luciferase assay substrates, genotyping kits, and camelid antibodies that have been validated for co-immunoprecipitation, histology, and flow cytometry. The Company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.